HealthQuill Health
About 400 million people globally live with alcohol and drug use disorders and of the total, 209 million people have alcohol dependence, according to a World Health Organization report.
Drugs Health Pharma

Alcohol claims 2.6 million lives yearly, 209m people are dependent: WHO

About 400 million people globally live with alcohol and drug use disorders and of the total, 209 million people have alcohol dependence, according.

Read More
Fifty-three nations have adopted best practice policies to eliminate trans fats in foods — benefitting 46% of the world’s population, or about 3.7 billion people, according to the UN.
Drugs Health Pharma

Global fight against trans fats proving successful as more nations join: UN

Fifty-three nations have adopted best practice policies to eliminate trans fats in foods — benefitting 46% of the world’s population, or about 3.7.

Read More
Israel’s Teva Pharmaceuticals will start selling a generic version of Novo Nordisk’s type 2 diabetic drug Victoza in the US market.
Drugs Health Pharma

Teva to sell generic version of Novo Nordisk’s diabetic drug in US

Israel’s Teva Pharmaceuticals will start selling a generic version of Novo Nordisk’s type 2 diabetic drug Victoza in the US market.

Read More
Novo Nordisk, a Danish pharmaceutical multinational, will invest $4.1 billion to build a new factory in the US to make obesity and chronic disease drugs, according to a company statement.
Drugs Health Pharma

Novo Nordisk to set up $4.1 billion injectables facility in US’s North Carolina

Novo Nordisk, a Danish pharmaceutical multinational, will invest $4.1 billion to build a new factory in the US to make obesity and chronic.

Read More
The US Food and Drug Administration has greenlighted Bristol Myers Squibb’s combination therapy to treat metastatic colorectal cancer in patients with a mutated gene.
Drugs Health Pharma

FDA gives nod to Bristol Myer’s colorectal cancer therapy

The US Food and Drug Administration has greenlighted Bristol Myers Squibb’s combination therapy to treat metastatic colorectal cancer in patients with a mutated.

Read More
Tirzepatide is an approved GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) treatment for chronic weight management, commercialised as Zepbound in the US and Mounjaro in some global markets outside the US.
Drugs Health Pharma

Eli Lilly’s Zepbound resolves sleep apnea in more than half of trial patients 

Tirzepatide, an obesity drug of  Eli Lilly and Company, has helped resolve moderate-to-severe obstructive sleep apnea in 52.% of adult patients in two.

Read More
A third of the world’s largest marine protected areas (MPAs) are indulging in destructive activities such as industrial fishing, a global study reveals.
Climate Health Pharma

A third of world’s largest marine protected areas exploited: Study

A third of the world’s largest marine protected areas (MPAs) are indulging in destructive activities such as industrial fishing, a global study reveals.

Read More
The World Health Organization has issued a medical product alert on falsified semaglutides, an active ingredient in Ozempic, a diabetic drug made by Novo Nordisk and weight-loss medication Wegovy.
Drugs Health Pharma

WHO issues medical alert on falsified weight-loss, diabetic drugs

The World Health Organization has issued a medical product alert on falsified semaglutides, an active ingredient in Ozempic, a diabetic drug made by.

Read More
Heatwaves are continuing to sweep across the world with “numerous record-breaking” high temperatures possible in the US, according to meteorological departments and weather services.
Climate Health Pharma

Heatwaves sweep across globe, Paris Olympic athletes may face the heat

Heatwaves are continuing to sweep across the world with “numerous record-breaking” high temperatures possible in the US, according to meteorological departments and weather.

Read More
Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.
Drugs Health Pharma

Roche to pay $42 million to Ascidian to make RNA exon editing drugs

Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.

Read More